234 related articles for article (PubMed ID: 7482824)
41. Recipient sensitization against donor cells in pre- and/or posttransplantation sera is inversely correlated with graft survival.
Sumitran S; Forsberg I; Lindholm A; Lundgren G; Möller E
Transplant Proc; 1987 Feb; 19(1 Pt 2):1566-7. PubMed ID: 3274384
[No Abstract] [Full Text] [Related]
42. Clinical development of Orthoclone OKT3.
Cosimi AB
Transplant Proc; 1987 Apr; 19(2 Suppl 1):7-16. PubMed ID: 3105142
[No Abstract] [Full Text] [Related]
43. T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action.
Brown SA; Lucas BA; Waid TH; McKeown JW; Barve S; Jackson LR; Thompson JS
Clin Transplant; 1996 Dec; 10(6 Pt 2):607-13. PubMed ID: 8996751
[TBL] [Abstract][Full Text] [Related]
44. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
[No Abstract] [Full Text] [Related]
45. Cytomegalovirus prophylaxis in pediatric renal transplant recipients.
So S; Mayo C; McCullough C; Jendrisak M; Woodle S; Marsh W; Bailey T
Transplant Proc; 1993 Feb; 25(1 Pt 2):1414-5. PubMed ID: 8382865
[No Abstract] [Full Text] [Related]
46. Selection criteria for antirejection therapy.
Wilmink JM
Transplant Proc; 1990 Dec; 22(6):2601-3; discussion 2603-4. PubMed ID: 2124742
[No Abstract] [Full Text] [Related]
47. Cadaveric renal transplantation against a positive historic crossmatch under tacrolimus immunosuppression: long-term follow-up.
Lyne JC; Vivas CA; Shapiro R; Scantlebury VP; Hakala TR; Starzl TE; Jordan ML
Transplant Proc; 1997; 29(1-2):312. PubMed ID: 9123015
[No Abstract] [Full Text] [Related]
48. Preliminary results from a randomized and prospective study of high-dose immunoglobulin versus monoclonal antibody in the rescue of steroid-resistant rejections.
Casadei D; Rial M; Argento J; Goldberg J; Raimondi E
Transplant Proc; 1998 Aug; 30(5):2164. PubMed ID: 9723428
[No Abstract] [Full Text] [Related]
49. A drug of the past, a lesson for the future.
Vincenti F
Pediatr Transplant; 2005 Jun; 9(3):267-8. PubMed ID: 15910379
[No Abstract] [Full Text] [Related]
50. Use of intravenous immunoglobulin in organ transplantation for noninfectious indications.
Yussim A; Klein T; Or H; Shaharabani E; Bar-Nathan N; Shmueli D; Lustig S; Sobolev V; Shapira Z
Transplant Proc; 1997 Nov; 29(7):3058-9. PubMed ID: 9365666
[No Abstract] [Full Text] [Related]
51. Optimization of cyclosporine monotherapy--long-term graft function.
Birkeland SA; Elbirk A; Rohr N; Jørgensen KA
Transplant Proc; 1994 Oct; 26(5):2501-6. PubMed ID: 7940767
[No Abstract] [Full Text] [Related]
52. Successful pancreas-renal transplantation without anti-T-cell antibody induction.
Shapiro ME; Abrams JM; Brown RS; Steinman TI; Strom TB
Transplant Proc; 1995 Dec; 27(6):3087-8. PubMed ID: 8539857
[No Abstract] [Full Text] [Related]
53. Humoral immune response against OKT3.
Chatenoud L
Transplant Proc; 1993 Apr; 25(2 Suppl 1):68-73. PubMed ID: 8465430
[No Abstract] [Full Text] [Related]
54. Anti-T12 monoclonal antibody therapy of acute renal allograft rejection.
Milford EL; Carpenter CB; Kirkman RL; Tilney NL; Mazoujian G; Strom TB; Lazarus JM; Schlossman SF; Guttmann RD; Lowry R
Transplant Proc; 1987 Feb; 19(1 Pt 3):1910. PubMed ID: 3274450
[No Abstract] [Full Text] [Related]
55. Kidney transplantation in children.
Cuhadaroğlu S; Velidedeoğlu E; Haberal M
Transplant Proc; 1993 Jun; 25(3):2174-5. PubMed ID: 8516858
[No Abstract] [Full Text] [Related]
56. Biological reagents for immunosuppressants.
Soulillou JP
Transplant Proc; 1995 Feb; 27(1):106-8. PubMed ID: 7878803
[No Abstract] [Full Text] [Related]
57. Case 6: benefits and risks of OKT3 treatment in renal transplantation.
First MR
Transplantation; 2001 Sep; 72(6):1177-8. PubMed ID: 11584824
[No Abstract] [Full Text] [Related]
58. Prophylactic use of the anti-IL-2 receptor monoclonal antibody LO-Tact-1 in cadaveric renal transplantation: results of a randomized study.
Kriaa F; Hiesse C; Alard P; Lantz O; Noury J; Charpentier B; Bazin H
Transplant Proc; 1993 Feb; 25(1 Pt 1):817-9. PubMed ID: 8438496
[No Abstract] [Full Text] [Related]
59. Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation.
Bruce DS; Newell KA; Woodle ES; Millis JM; Piper JB; Huss E; Thistlethwaite JR
Transplant Proc; 1996 Aug; 28(4):2136-7. PubMed ID: 8769180
[No Abstract] [Full Text] [Related]
60. A U.S. clinical study of Orthoclone OKT3 in renal transplantation.
Norman DJ; Shield CF; Barry J; Henell K; Funnell MB; Lemon J
Transplant Proc; 1987 Apr; 19(2 Suppl 1):21-7. PubMed ID: 3105136
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
